Heart failure is a common complication after acute myocardial infarction in patients with diabetes: A nationwide study in the SWEDEHEART registry

被引:36
作者
Ritsinger, Viveca [1 ,2 ]
Nystrom, Thomas [3 ]
Saleh, Nawsad [1 ]
Lagerqvist, Bo [4 ,5 ]
Norhammar, Anna [1 ,6 ]
机构
[1] Karolinska Univ Hosp, Karolinska Inst, Dept Med K2, Cardiol Unit, S1 02, SE-17176 Stockholm, Sweden
[2] Reg Kronoberg, Dept Res & Dev, Vaxjo, Sweden
[3] Karolinska Univ Hosp, Karolinska Inst, Dept Clin Sci & Educ, Sodersjukhuset, Stockholm, Sweden
[4] Uppsala Univ, Cardiol, Dept Med Sci, Uppsala, Sweden
[5] Uppsala Univ, Uppsala Clin Res Ctr, Uppsala, Sweden
[6] Capio St Gorans Hosp, Stockholm, Sweden
关键词
Heart failure; diabetes; acute myocardial infarction; prognosis; CARDIOVASCULAR OUTCOMES; PROGNOSTIC IMPLICATIONS; NA+/H+ EXCHANGER; MORTALITY; EMPAGLIFLOZIN; INHIBITION; MELLITUS; DISEASE;
D O I
10.1177/2047487319901063
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Several glucose lowering drugs with preventive effects on heart failure and death have entered the market, however, still used in low proportions after acute myocardial infarction. We explored the complication rates of heart failure and death after acute myocardial infarction in patients with and without diabetes. Methods All patients (N = 73,959) with acute myocardial infarction admitted for coronary angiography included in the SWEDEHEART registry during the years 2012-2017 were followed for heart failure (until 31 December 2017) and mortality (until 30 June 2018); mean follow-up time 1223 (SD +/- 623) days. Results Mean age was 69 years (SD +/- 12), 69% were male and 24% had diabetes. Heart failure occurred more often in diabetes (22% vs. 12% if no diabetes), especially if previous MI (33% vs. 23%). Patients with diabetes had increased risk of HF regardless of previous myocardial infarction (MI); with previous MI adjusted hazard ratio 2.09 (95% confidence interval 1.96-2.20) and without MI 1.52 (1.44-1.61) respectively when non-diabetes patients with first MI served as reference. In patients with no previous heart failure or MI and discharged with left ventricular ejection fraction >= 50% the risk of heart failure was particularly high in those with diabetes (1.56; 1.39-1.76) when compared with those without. Similar findings were seen for death and combined event (heart failure and death). Conclusions Heart failure is a common complication after acute myocardial infarction in diabetes, increasing the risk by 50-60% regardless of previous heart failure or MI. This risk is present even with normal reported left ventricular ejection fraction, indicating the existence of a large diabetes population at heart failure risk after acute myocardial infarction.
引用
收藏
页码:1890 / 1901
页数:12
相关论文
共 28 条
[1]   Real-world use and modeled impact of glucose-lowering therapies evaluated in recent cardiovascular outcomes trials: An NCDR® Research to Practice project [J].
Arnold, Suzanne V. ;
Inzucchi, Silvio E. ;
Tang, Fengming ;
McGuire, Darren K. ;
Mehta, Sanjeev N. ;
Maddox, Thomas M. ;
Goyal, Abhinav ;
Sperling, Laurence S. ;
Einhorn, Daniel ;
Wong, Nathan D. ;
Khunti, Kamlesh ;
Lam, Carolyn S. P. ;
Kosiborod, Mikhail .
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2017, 24 (15) :1637-1645
[2]   Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits [J].
Baartscheer, Antonius ;
Schumacher, Cees A. ;
Wust, Rob C. I. ;
Fiolet, Jan W. T. ;
Stienen, Ger J. M. ;
Coronel, Ruben ;
Zuurbier, Coert J. .
DIABETOLOGIA, 2017, 60 (03) :568-573
[3]   Molecular mechanisms of diabetic cardiomyopathy [J].
Bugger, Heiko ;
Abel, E. Dale .
DIABETOLOGIA, 2014, 57 (04) :660-671
[4]   2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD [J].
Cosentino, Francesco ;
Grant, Peter J. ;
Aboyans, Victor ;
Bailey, Clifford J. ;
Ceriello, Antonio ;
Delgado, Victoria ;
Federici, Massimo ;
Filippatos, Gerasimos ;
Grobbee, Diederick E. ;
Hansen, Tina Birgitte ;
Huikuri, Heikki, V ;
Johansson, Isabelle ;
Juni, Peter ;
Lettino, Maddalena ;
Marx, Nikolaus ;
Mellbin, Linda G. ;
Ostgren, Carl J. ;
Rocca, Bianca ;
Roffi, Marco ;
Sattar, Naveed ;
Seferovic, Petar M. ;
Sousa-Uva, Miguel ;
Valensi, Paul ;
Wheeler, David C. ;
Piepoli, Massimo Francesco ;
Birkeland, Kare, I ;
Adamopoulos, Stamatis ;
Ajjan, Ramzi ;
Avogaro, Angelo ;
Baigent, Colin ;
Brodmann, Marianne ;
Bueno, Hector ;
Ceconi, Claudio ;
Chioncel, Ovidiu ;
Coats, Andrew ;
Collet, Jean-Philippe ;
Collins, Peter ;
Cosyns, Bernard ;
Di Mario, Carlo ;
Fisher, Miles ;
Fitzsimons, Donna ;
Halvorsen, Sigrun ;
Hansen, Dominique ;
Hoes, Arno ;
Holt, Richard I. G. ;
Home, Philip ;
Katus, Hugo A. ;
Khunti, Kamlesh ;
Komajda, Michel ;
Lambrinou, Ekaterini .
EUROPEAN HEART JOURNAL, 2020, 41 (02) :255-323
[5]  
Davies MJ, 2018, DIABETES CARE, V41, P2669, DOI [10.1007/s00125-018-4729-5, 10.2337/dci18-0033]
[6]   CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis [J].
Ferrannini, Ele ;
Mark, Michael ;
Mayoux, Eric .
DIABETES CARE, 2016, 39 (07) :1108-1114
[7]   Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA- REG OUTCOME Trial [J].
Fitchett, David ;
Inzucchi, Silvio E. ;
Cannon, Christopher P. ;
McGuire, Darren K. ;
Scirica, Benjamin M. ;
Johansen, Odd Erik ;
Sambevski, Steven ;
Kaspers, Stefan ;
Pfarr, Egon ;
George, Jyothis T. ;
Zinman, Bernard .
CIRCULATION, 2019, 139 (11) :1384-1395
[8]   Type 2 diabetes and heart failure: Characteristics and prognosis in preserved, mid-range and reduced ventricular function [J].
Johansson, Isabelle ;
Dahlstrom, Ulf ;
Edner, Magnus ;
Nasman, Per ;
Ryden, Lars ;
Norhammar, Anna .
DIABETES & VASCULAR DISEASE RESEARCH, 2018, 15 (06) :494-503
[9]   Prognostic Implications of Type 2 Diabetes Mellitus in Ischemic and Nonischemic Heart Failure [J].
Johansson, Isabelle ;
Dahlstrom, Ulf ;
Edner, Magnus ;
Nasman, Per ;
Ryden, Lars ;
Norhammar, Anna .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 68 (13) :1404-1416
[10]   Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus [J].
Kato, Eri T. ;
Silverman, Michael G. ;
Mosenzon, Ofri ;
Zelniker, Thomas A. ;
Cahn, Avivit ;
Furtado, Remo H. M. ;
Kuder, Julia ;
Murphy, Sabina A. ;
Bhatt, Deepak L. ;
Leiter, Lawrence A. ;
McGuire, Darren K. ;
Wilding, John P. H. ;
Bonaca, Marc P. ;
Ruff, Christian T. ;
Desai, Akshay S. ;
Goto, Shinya ;
Johansson, Peter A. ;
Gause-Nilsson, Ingrid ;
Johanson, Per ;
Langkilde, Anna Maria ;
Raz, Itamar ;
Sabatine, Marc S. ;
Wiviott, Stephen D. .
CIRCULATION, 2019, 139 (22) :2528-2536